Literature DB >> 27279607

Role of Conserved E2 Residue W420 in Receptor Binding and Hepatitis C Virus Infection.

Vanessa M Cowton1, Allan G N Angus1, Sarah J Cole1, Christina K Markopoulou1, Ania Owsianka1, James I Dunlop1, Deborah E Gardner1, Thomas Krey2,3,4,5, Arvind H Patel6.   

Abstract

UNLABELLED: Hepatitis C virus (HCV) enters cells via interactions with several host factors, a key one being that between the viral E2 envelope glycoprotein and the CD81 receptor. We previously identified E2 tryptophan residue 420 (W420) as an essential CD81-binding residue. However, the importance of W420 in the context of the native virion is unknown, as those previous studies predate the infectious HCV cell culture (cell culture-derived HCV [HCVcc]) system. Here, we introduced four separate mutations (F, Y, A, or R) at position 420 within the infectious HCVcc JFH-1 genome and characterized their effects on the viral life cycle. While all mutations reduced E2-CD81 binding, only two (W420A and W420R) reduced HCVcc infectivity. Further analyses of mutants with hydrophobic residues (F or Y) found that interactions with the receptors SR-BI and CD81 were modulated, which in turn determined the viral uptake route. Both mutant viruses were significantly less dependent on SR-BI, and its lipid transfer activity, for virus entry. Furthermore, these viruses were resistant to the drug erlotinib, which targets epidermal growth factor receptor (EGFR) (a host cofactor for HCV entry) and also blocks SR-BI-dependent high-density lipoprotein (HDL)-mediated enhancement of virus entry. Together, our data indicate a model where an alteration at position 420 causes a subtle change in the E2 conformation that prevents interaction with SR-BI and increases accessibility to the CD81-binding site, in turn favoring a particular internalization route. These results further show that a hydrophobic residue with a strong preference for tryptophan at position 420 is important, both functionally and structurally, to provide an additional hydrophobic anchor to stabilize the E2-CD81 interaction. IMPORTANCE: Hepatitis C virus (HCV) is a leading cause of liver disease, causing up to 500,000 deaths annually. The first step in the viral life cycle is the entry process. This study investigates the role of a highly conserved residue, tryptophan residue 420, of the viral glycoprotein E2 in this process. We analyzed the effect of changing this residue in the virus and confirmed that this region is important for binding to the CD81 receptor. Furthermore, alteration of this residue modulated interactions with the SR-BI receptor, and changes to these key interactions were found to affect the virus internalization route involving the host cofactor EGFR. Our results also show that the nature of the amino acid at this position is important functionally and structurally to provide an anchor point to stabilize the E2-CD81 interaction.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27279607      PMCID: PMC4984626          DOI: 10.1128/JVI.00685-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  76 in total

1.  Study of a novel hypervariable region in hepatitis C virus (HCV) E2 envelope glycoprotein.

Authors:  Myriam Troesch; Isabelle Meunier; Pascal Lapierre; Normand Lapointe; Fernando Alvarez; Marc Boucher; Hugo Soudeyns
Journal:  Virology       Date:  2006-06-16       Impact factor: 3.616

2.  CD81 extracellular domain 3D structure: insight into the tetraspanin superfamily structural motifs.

Authors:  K Kitadokoro; D Bordo; G Galli; R Petracca; F Falugi; S Abrignani; G Grandi; M Bolognesi
Journal:  EMBO J       Date:  2001-01-15       Impact factor: 11.598

3.  Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes.

Authors:  K G Hadlock; R E Lanford; S Perkins; J Rowe; Q Yang; S Levy; P Pileri; S Abrignani; S K Foung
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 4.  Assembly of infectious hepatitis C virus particles.

Authors:  Ralf Bartenschlager; Francois Penin; Volker Lohmann; Patrice André
Journal:  Trends Microbiol       Date:  2010-12-14       Impact factor: 17.079

5.  Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding.

Authors:  Arvind H Patel; Jonny Wood; Francois Penin; Jean Dubuisson; J A McKeating
Journal:  J Gen Virol       Date:  2000-12       Impact factor: 3.891

6.  Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance.

Authors:  Justin R Bailey; Lisa N Wasilewski; Anna E Snider; Ramy El-Diwany; William O Osburn; Zhenyong Keck; Steven K H Foung; Stuart C Ray
Journal:  J Clin Invest       Date:  2014-12-15       Impact factor: 14.808

7.  Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture.

Authors:  Kyung-Soo Chang; Jieyun Jiang; Zhaohui Cai; Guangxiang Luo
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

8.  Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies.

Authors:  Annalisa Meola; Alexander W Tarr; Patrick England; Luke W Meredith; C Patrick McClure; Steven K H Foung; Jane A McKeating; Jonathan K Ball; Felix A Rey; Thomas Krey
Journal:  J Virol       Date:  2014-12-03       Impact factor: 5.103

Review 9.  Genetic diversity and evolution of hepatitis C virus--15 years on.

Authors:  Peter Simmonds
Journal:  J Gen Virol       Date:  2004-11       Impact factor: 3.891

10.  Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.

Authors:  Alexander W Tarr; Ania M Owsianka; Judith M Timms; C Patrick McClure; Richard J P Brown; Timothy P Hickling; Thomas Pietschmann; Ralf Bartenschlager; Arvind H Patel; Jonathan K Ball
Journal:  Hepatology       Date:  2006-03       Impact factor: 17.425

View more
  6 in total

1.  Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design.

Authors:  Brian G Pierce; Zhen-Yong Keck; Patrick Lau; Catherine Fauvelle; Ragul Gowthaman; Thomas F Baumert; Thomas R Fuerst; Roy A Mariuzza; Steven K H Foung
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-26       Impact factor: 11.205

Review 2.  Hepatitis C Virus Envelope Glycoproteins: A Balancing Act of Order and Disorder.

Authors:  Samantha A Yost; Yuanyuan Wang; Joseph Marcotrigiano
Journal:  Front Immunol       Date:  2018-08-24       Impact factor: 7.561

3.  The Neutralizing Antibody Responses of Individuals That Spontaneously Resolve Hepatitis C Virus Infection.

Authors:  Vanessa M Cowton; James I Dunlop; Sarah J Cole; Rachael E Swann; Arvind H Patel
Journal:  Viruses       Date:  2022-06-25       Impact factor: 5.818

4.  An entropic safety catch controls hepatitis C virus entry and antibody resistance.

Authors:  Lenka Stejskal; Mphatso D Kalemera; Charlotte B Lewis; Machaela Palor; Lucas Walker; Tina Daviter; William D Lees; David S Moss; Myrto Kremyda-Vlachou; Zisis Kozlakidis; Giulia Gallo; Dalan Bailey; William Rosenberg; Christopher J R Illingworth; Adrian J Shepherd; Joe Grove
Journal:  Elife       Date:  2022-07-07       Impact factor: 8.713

5.  Predicting the Effectiveness of Hepatitis C Virus Neutralizing Antibodies by Bioinformatic Analysis of Conserved Epitope Residues Using Public Sequence Data.

Authors:  Vanessa M Cowton; Joshua B Singer; Robert J Gifford; Arvind H Patel
Journal:  Front Immunol       Date:  2018-06-27       Impact factor: 7.561

6.  A polymorphic residue that attenuates the antiviral potential of interferon lambda 4 in hominid lineages.

Authors:  Connor G G Bamford; Elihu Aranday-Cortes; Ines Cordeiro Filipe; Swathi Sukumar; Daniel Mair; Ana da Silva Filipe; Juan L Mendoza; K Christopher Garcia; Shaohua Fan; Sarah A Tishkoff; John McLauchlan
Journal:  PLoS Pathog       Date:  2018-10-11       Impact factor: 6.823

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.